Associations of paediatric demyelinating and encephalitic syndromes with myelin oligodendrocyte glycoprotein antibodies: a multicentre observational study - 19/02/20
, Gemma Olivé-Cirera, MD a, c, Eugenia Martínez-Hernandez, MD a, Maria Sepulveda, MD a, Raquel Ruiz-Garcia, PhD d, Marta Muñoz-Batista, BS a, Helena Ariño, MD a, Veronica González-Álvarez, MD b, Ana Felipe-Rucián, MD e, Maria Jesús Martínez-González, MD f, Veronica Cantarín-Extremera, MD g, Maria Concepción Miranda-Herrero, MD h, Lorena Monge-Galindo, MD i, Miguel Tomás-Vila, MD j, Elena Miravet, MD k, Ignacio Málaga, MD l, Georgina Arrambide, MD m, Cristina Auger, MD n, Mar Tintoré, ProfMD m, Xavier Montalban, ProfMD m, o, Adeline Vanderver, MD p, q, Francesc Graus, ProfMD a, Albert Saiz, ProfMD a, Josep Dalmau, ProfMD a, q, r, ⁎ on behalf of the
Spanish Pediatric anti-MOG Study Group†
Summary |
Background |
Investigations of myelin oligodendrocyte glycoprotein (MOG) antibodies are usually focused on demyelinating syndromes, but the entire spectrum of MOG antibody-associated syndromes in children is unknown. In this study, we aimed to determine the frequency and distribution of paediatric demyelinating and encephalitic syndromes with MOG antibodies, their response to treatment, and the phenotypes associated with poor prognosis.
Methods |
In this prospective observational study, children with demyelinating syndromes and with encephalitis other than acute disseminated encephalomyelitis (ADEM) recruited from 40 secondary and tertiary centres in Spain were investigated for MOG antibodies. All MOG antibody-positive cases were included in our study, which assessed syndromes, treatment and response to treatment (ie, number of relapses), outcomes (measured with the modified Rankin scale [mRS]), and phenotypes associated with poor prognosis. We used Fisher’s exact and Wilcoxon rank sum tests to analyse clinical features, and survival Cox regression to analyse time to antibody negativity.
Findings |
Between June 1, 2013, and Dec 31, 2018, 239 children with demyelinating syndromes (cohort A) and 296 with encephalitis other than ADEM (cohort B) were recruited. 116 patients had MOG antibodies, including 94 (39%) from cohort A and 22 (7%) from cohort B; 57 (49%) were female, with a median age of 6·2 years (IQR 3·7–10·0). Presenting syndromes in these 116 patients included ADEM (46 [68%]), encephalitis other than ADEM (22 [19%]), optic neuritis (20 [17%]), myelitis (13 [11%]), neuromyelitis optica spectrum disorders (six [5%]), and other disorders (nine [8%]). Among the patients with autoimmune encephalitis in cohort B (n=64), MOG antibodies were more common than all neuronal antibodies combined (22 [34%] vs 21 [33%]). After a median follow-up of 42 months (IQR 22–67), 33 (28%) of the 116 patients had relapses, including 17 (17%) of 100 diagnosed at first episode. Steroids, intravenous immunoglobulin, or plasma exchange were used in 100 (86%) patients at diagnosis, and 32 (97%) of 33 at relapses. Rituximab was mainly used at relapses (11 [33%]). 99 (85%) of 116 patients had substantial recovery (mRS <2) and 17 (15%) moderate to severe deficits (mRS >2; one died). Phenotypes of poor prognosis included ADEM-like relapses progressing to leukodystrophy-like features, and extensive cortical encephalitis evolving to atrophy. Time to antibody negativity was longer in patients with relapses (HR 0·18, 95% CI 0·05–0·59).
Interpretation |
The spectrum of paediatric MOG antibody-associated syndromes is wider than previously reported and includes demyelinating syndromes and encephalitis. Recognition of these disorders has important clinical and prognostic implications.
Funding |
Mutua Madrileña Foundation; ISCIII–Subdirección General de Evaluación y Fomento de la Investigación Sanitaria; Fondo Europeo de Desarrollo Regional; Pediatrics Spanish Society; Departament de Salut, Generalitat de Catalunya; Marato TV3 Foundation; Red Española de Esclerosis Múltiple; La Caixa Foundation; and Fundació CELLEX.
Le texte complet de cet article est disponible en PDF.Plan
Vol 19 - N° 3
P. 234-246 - mars 2020 Retour au numéro
Article précédent
- Safety and efficacy of GABAA ?5 antagonist S44819 in patients with ischaemic stroke: a multicentre, double-blind, randomised, placebo-controlled trial
- Hugues Chabriat, Claudio L Bassetti, Ute Marx, Marie-Laure Audoli-Inthavong, Aurore Sors, Estelle Lambert, Marine Wattez, Dirk M Hermann, RESTORE BRAIN study investigators, Katharina ALTHAUS, Sergi AMARO, Hee-Joon BAE, Zbigniew BAK, Leonardo BARBARINI, Pietro BASSI, Rodrigo BAZAN, Daniel BERECZKI, Tomasz BERKOWICZ, Joerg BERROUSCHOT, Dylan BLACQUIERE, Waldemar BROLA, Kenneth BUTCHER, Pere CARDONA, Jae-Kwan CHA, Geoffrey CLOUD, David COHEN, Charlotte CORDONNIER, Attila CSANYI, Anna CZLONKOWSKA, Stephen DAVIS, Jesse DAWSON, Nina DE KLIPPEL, Christian DENIER, Philippe DESFONTAINES, Hans-Christoph DIENER, Peter DIOSZEGHY, Diederik Willem DIPPEL, Laura DORADO, Andras FOLYOVICH, Gabriel Rodriguez FREITAS, Mauricio Andre FRIEDRICH, Waldemar FRYZE, Rubens Jose GAGLIARDI, Marianna GOTTSCHAL, Rohan GRIMLEY, Martin GROND, Klaus GRÖSCHEL, Hassan HOSSEINI, Yangha HWANG, Bernd KALLMUENZER, Usman KHAN, Jong Sung KIM, Tim KLEINIG, Agnes KOVES, Aida LAGO MARTIN, Anetta LASEK-BAL, Giuseppe LEMBO, Robin LEMMENS, Ralf LINDERT, Luiz Carlos PORCELLO MARRONE, Maite MARTINEZ ZABALETA, Jean-Louis MAS, Jaime MASJUAN VALLEJO, Mikael MAZIGHI, Cesar MINELLI, Amit MISTRI, Carlos MOLINA, Francisco MONICHE ALVAREZ, Carla Heloisa CABRAL MORO, Wim MULLENERS, Darius NABAVI, Jean-Philippe NEAU, Bill O’BRIEN, Csaba OVARY, Gyula PANCZEL, Man Seok PARK, Thanh PHAN, Suzanne RAGAB, Konrad REJDAK, Gabriel RODRIGUEZ DE FREITAS, Christine ROFFE, Jaume ROQUER GONZALEZ, Luisa ROVER, Gisele SAMPAIO SILVA, Peter SCHELLINGER, Tomas SEGURA MARTIN, Louise SHAW, Igor SIBON, Ondrej SKODA, Didier SMADJA, Piotr SOBOLEWSKI, Hassan SODA, Nikola SPRIGG, Maciej SWIAT, Laszlo SZAPARY, Norbert SZEGEDI, Danilo TONI, Attila VALIKOVICS, Geert VANHOOREN, Laszlo VECSEI, Theodore WEIN, Andrew WONG, Alvaro XIMENEZ CARRILLO
- ?-adrenoreceptors and the risk of Parkinson’s disease
- Franziska Hopfner, Günter U Höglinger, Gregor Kuhlenbäumer, Anton Pottegård, Mette Wod, Kaare Christensen, Caroline M Tanner, Günther Deuschl
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?